Phase 3 N=60 A Human Trial to Evaluate the Efficacy and Safety of Fermented Turmeric in Subjects Showing Mild Hepatic Injury
Mild Hepatic Injury
Primary: Changes in ALT(Alanine Transaminase) — 61.08; 55.68; 44.92; 53.82 IU/L
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=24 Evaluation Of Hepatic Impairment On AG-013736 Pharmacokinetics
Hepatic Insufficiency
Primary: Maximum Observed Plasma Concentration (Cmax) — 30.43; 26.96; 38.85 ng/mL
Phase 3 N=95 Is Adrenal Insufficiency Under-diagnosed in Hospitalized Cirrhosis Patients?
Adrenal Insufficiency · Cirrhosis · Spur Cell Anemia
Primary: Number of Participants With Cholesterol Esterification Deficiency — 10; 11 Participants
Phase 2 N=18 Use of F-652 in Patients With Alcoholic Hepatitis
Alcoholic Hepatitis
Primary: The Number of Subjects With Unexpected Serious Adverse Events. — 0; 0; 0 Participants
Phase 3 N=76 13C-Methacetin Breath Test for the Prediction of Outcome in in ALI or ALF
Acute Liver Failure
Primary: Peak Percent Dose Recovery (PDR) Value — 10.2; 1.9 percentage per hour
N/A N=34 Transient Elastography in Autoimmune Hepatitis
Liver Cirrhosis
Primary: Sensitivity and Specifity of Transient Elastography in Detection of Liver Cirrhosis — 0.83; 1.00; 1.00; 0.97 Probability
Phase 4 N=276 Aminotransferase Trends During Prolonged Acetaminophen Dosing
Drug Toxicity · Healthy
Primary: The Proportion of Subjects Treated With Long-term Acetaminophen (4 g/Day) That Develops Persistent ALT Elevations. — 204; 47; 1; 0 participants
Phase 2 N=18 An Open Label Study to Assess the Effect of BLI800 on Safety and Clinical Chemistry Parameters
Colonoscopy · Bowel Preparation
Primary: Maximum Observed Concentration (Cmax) — 717.0; 499.5; 560.2 µmol/L
Phase 1 N=35 Influence of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of Various Doses of Afatinib
Liver Diseases · Healthy
Primary: Area Under Curve From 0 to Infinity (AUC0-infinity) — 886; 552; 934; 956 ng*h/mL — p=0.1998
Phase 4 N=276 Detection of Liver Fibrosis With Magnetic Resonance Imaging (MRI)
Chronic Liver Disease
Primary: PV Flow — 16.0; 15.5; 23.2; 27.1 ml/s
Phase 2 N=47 Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury
Acute Liver Failure · Acute Liver Injury
Primary: Number of Participants That do Not Tolerate the Administered Dose and Had Grade 3 or 4 Treatment Emergent Adverse Events as a Measure of Safety and Tolerability — 0; 0…
N/A N=40 Noninvasive Biomarkers of Metabolic Liver Disease 1.1
Nonalcoholic Steatohepatitis · Nonalcoholic Fatty Liver
Primary: Evaluation of Pooled Different-day, Different-operator Reproducibility of Shear Wave Speed Measurements — 30.7 Reproducibility coefficient (in %)
N/A N=5 Adult Stem Cell Therapy in Liver Insufficiency
Liver Cirrhosis
Primary: Number of Participants With Serious Adverse Events Related to Injection — 0 Participants
N/A N=67 Markers of Liver Apoptosis After Anesthesia With Sevoflurane or Propofol
Liver Dysfunction
Primary: Changes in the M30 and M65 Markers Related to the Anesthesia Type — 237.27; 279.97; 427.33; 470.30 U/L
Phase 1 N=2 Open Label Single Dose Phase I Trial of BI 201335 to Study Pharmacokinetics and Safety in Patients With Compensated Liver Cirrhosis
Hepatitis C · Liver Cirrhosis
Primary: AUC 0-∞ — 7240; 24700 h*ng/mL
Phase 1 N=38 A Study of The Effect of Hepatic Impairment on The Pharmacokinetics of Aleglitazar
Healthy Volunteer
Primary: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) of Aleglitazar — 98.5; 113; 151 hours (h)*nanogram (ng)/milliliter (mL)
Phase 1 N=33 Nintedanib in Volunteers With Hepatic Impairment Compared With Healthy Volunteers
Hepatic Insufficiency
Primary: AUC (0-inf) of Nintedanib — 200; 674; 92.7; 77.8 ng*h/mL
Phase 4 N=130 Effect of Probiotics on Gut-Liver Axis of Alcoholic Liver Disease
Alcoholic Liver Disease
Primary: Liver Enzymes(ALT) — 66; 48 IU/L
Phase 1 N=22 Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment
Hepatic Impairment · Healthy
Primary: Cmax — 538.1; 533.4; 429 ng/mL
N/A N=2,600 Chinese CLIF-C Acute-on-Chronic Liver Disease and Liver Failure Study
Liver Failure, Acute on Chronic
Primary: 28-day Mortality,28-day Liver-transplantation Free Mortality& 28-day Liver Transplantation Rate — 74; 124; 74 Participants
N/A N=28 Chronic Liver Disease in Urea Cycle Disorders
Urea Cycle Disorder
Primary: Liver Stiffness as Measured by Shear Wave Elastography — 13; 14 Participants
Early Phase 1 N=16 Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants
Moderate Hepatic Impairment
Primary: Maximum Plasma Concentration (Cmax) of Pexidartinib Following a Single Dose in Participants With Moderate Hepatic Impairment Compared to Healthy Participants — 1420…
N/A N=101 Normal Liver Stiffness by MR Elastography
Liver Diseases
Primary: Liver Stiffness — 2.1 kPa
Phase 2 N=80 Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease
Nonalcoholic Fatty Liver · Nonalcoholic Steatohepatitis
Primary: Absolute Change in Intrahepatic Lipid Content, by 1H-MRS — -6.6; 3.6 Mean absolute percentage change
N/A N=48 Intra-Individual Reproducibility of the Non-Invasive Assessment of the Portal Circulation
Hepatitis C, Chronic · Non-Alcoholic Fatty Liver Disease
Primary: Cholate Shunt Test — 28.0; 37.6; 33.4 SHUNT %
N/A N=84 Liver Fat Quantification by Magnetic Resonance Imaging (MRI) - Prediction of Postoperative Complications
Fatty Liver · Surgery
Primary: Percentage of Liver Fat Content on MRI in Patients With Serious Post-operative Complications (Clavien-Dindo Grade ≥IV) — 1.3; 13.6 Percentage of liver fat content
Phase 2 N=78 Phase II Trial of Silymarin for Non-Cirrhotic Patients With Non-Alcoholic Steatohepatitis
Non-alcoholic Steatohepatitis
Primary: Efficacy - Improvement by at Least 2 Points in Histology (NAS) — 5; 4; 3 participants
N/A N=55 Determination of Liver Stiffness in Chronic Liver Disease Patients by Acoustic Radiation Force Imaging (ARFI) Ultrasound
Chronic Liver Disease
Primary: Agreement in Measured Liver Stiffness Between ARFI and MRE — 3.21; 2.48; 1.81; 2.0 kPa
Phase 1 N=24 Study of PF-05221304 in Subjects With Varying Degrees of Hepatic Impairment
Hepatic Impairment
Primary: Maximum Plasma Concentration (Cmax) of PF-05221304 — 1220; 1591; 1433; 1592 Nanogram per milliliter (ng/mL)
Phase 1 N=24 A Hepatic Impairment Study for PF-04965842.
Hepatic Impairment
Primary: Maximum Observed Plasma Concentration (Cmax) for PF-04965842 — 1352; 1276; 1426 nanogram per milliliter (ng/mL)